BALTIMORE, Aug. 9, 2023 /PRNewswire/ — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new synthetic THC analog, today announced that management will participate in the…